| 行业分析 |
|
|
|
|
| 全球寡核苷酸类药物开发现状与趋势 |
毛开云,陈大明,范月蕾,王跃,江洪波( ) |
| 中国科学院上海生命科学信息中心 上海 200031 |
|
| Development Status and Trend Analysis of Oligonucleotide Therapies |
| Kai-yun MAO,Da-ming CHEN,Yue-lei FAN,Yue WANG,Hong-bo JIANG() |
| Shanghai Information Center for Life Sciences, Chinese Academy of Sciences, Shanghai 200031, China |
引用本文:
毛开云,陈大明,范月蕾,王跃,江洪波. 全球寡核苷酸类药物开发现状与趋势[J]. 中国生物工程杂志, 2018, 38(4): 96-106.
Kai-yun MAO,Da-ming CHEN,Yue-lei FAN,Yue WANG,Hong-bo JIANG. Development Status and Trend Analysis of Oligonucleotide Therapies. China Biotechnology, 2018, 38(4): 96-106.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20180413
或
https://manu60.magtech.com.cn/biotech/CN/Y2018/V38/I4/96
|
| [1] |
Stein C A, Castanotto D . FDA-approved oligonucleotide therapies in 2017. Molecular Therapy. 2017,25(5):1069-1075.
doi: 10.1016/j.ymthe.2017.03.023
|
| [2] |
Fei J. The development technology of small nucleic acid drug. Beijing: Military Medical Science Press, 2011, 1-5.
|
| [3] |
Geary R S, Baker B F, Crooke S T . Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro((r))): A second-generation antisense oligonucleotide inhibitor of apolipoprotein b. Clinical Pharmacokinetics, 2015,54(2):133-146.
doi: 10.1007/s40262-014-0224-4
pmid: 4305106
|
| [4] |
Bishop K M, Montes J, Finkel R S . Motor milestone aassessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam-Part 2: Experience from a nusinersen clinical study. Muscle & Nerve, 2018,57(1):143-146.
doi: 10.1002/mus.25705
pmid: 28556387
|
| [5] |
Macaulay R, Evans J . The FDA approval of eteplirsen - necessary flexibility or a worrying precedent? Value In Health, 2017,20(9):A728-A728.
|
| [6] |
Stein C Y, Castanotto D, Krishnan A . Defibrotide (Defitelio): A new addition to the stockpile of food and drug administration-approved oligonucleotide drugs. Molecular Therapy-Nucleic Acids, 2016, ( 5):e346
doi: 10.1038/mtna.2016.42
|
| [7] |
Mitchell W M . Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Expert Review of Clinical Pharmacology, 2016,9(6):755-770.
doi: 10.1586/17512433.2016.1172960
pmid: 4917909
|
| [8] |
Earnshaw S R, Javitt J C, Zlateva G P . Cost-effectiveness model for age-related macular degeneration: Comparing early and late macugen treatment. Value In Health, 2005,8(6):A177-A177.
|
| [9] |
Bejanian M, Lieberman R M, Goldstein D A . A pharmacokinetic study of intravitreal fomivirsen (Vitravene (TM)) in patients with CMVR. Investigative Ophthalmology & Visual Science. 1999,40(4):S874-S874.
|
| [10] |
Adams D, Suhr O B , Dyck P J et al. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. Bmc Neurology, 2017,17:181.
doi: 10.1186/s12883-017-0948-5
pmid: 28893208
|
| [11] |
Gouni-Berthold I, Alexander V, Digenio A , et al. Apolipoprotein C-Iii inhibition with volanesorsen in patients with hypertriglyceridemia (compass): A randomized, double-blind, pbo-controlled trial. Clinical Cardiology, 2017,40(1):13-14.
doi: 10.1016/j.jacl.2017.04.038
|
| [12] |
Wang A K, Coehlo T,Waddington-Cruz M et al . Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (NEURO-TTR).142nd Annual Meeting of the American-Neurological-Association (ANA). San Diego, CA. OCT 15-17, 2017.
|
| [13] |
Jairath V, Khanna R, Feagan, Brian G . Alicaforsen for the treatment of inflammatory bowel disease. Expert Opinion on Investigational Drugs. 2017,26(8):991-997.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
